# US 2023/0057086 A1 · Provision of bacteriophages in various dosage forms and bacteriophage application device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057086 A1
- Document ID: US20230057086A1
- Status: Published application
- Kind: A1
- Application number: 17/792,885
- Filed: 2020-11-21
- Published: 2023-02-23
- Earliest claimed: 2020-01-14
- Assignees: PhaTEC GmbH
- Applicants: PhaTEC GmbH
- Inventors: Simon Frank Junghans; Justus Gross
- Web page: https://patentgrep.com/patent/US20230057086A1

## CPC

- A61K 9/5184: {Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61L 17/005: {containing a biologically active substance, e.g. a medicament or a biocide}
- A61L 26/0061: {Use of materials characterised by their function or physical properties}
- A61L 26/0066: {Medicaments; Biocides}
- A61L 26/008: {Hydrogels or hydrocolloids}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/04: Antibacterial agents
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- C12N 2795/00: Bacteriophages
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to bacteriophage means, namely intracorporal bacteriophage means, nasopharyngeal and pulmonary bacteriophage means, cutaneous bacteriophage means, and bacteriophage suture means, and in addition a two-syringe bacteriophage means, a nasopharyngeal and pulmonary bacteriophage means device, and a bacteriophage sensitive testing application.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

An intracorporal bacteriophage material or composition, comprising:
a) a sterile bacteriophage gel, wherein said gel is release-modulatable; or
b) sterile bacteriophage soft capsules comprising a gel; or
c) sterile soft capsule chain comprising a bacteriophage soft capsules having a gel on a monofilamentous hydrolytically degradable filament or on a non-degradable material; or
d) a sterile bacteriophage sponge, wherein the sponge is sprayed with a bacteriophage solution or a bacteriophage gel, or a bacteriophage gel is freeze-dried.

### Claim 10

A naso-pharyngeal and pulmonary bacteriophage material or composition, comprising:
a bacteriophage solution or as a bacteriophage powder,
wherein the bacteriophage material or composition is nebulizable using at least one of the following:
nebulization via respirator using a phage nebulization device;
nebulization via pressurized gas metered dose aerosols;
nebulization via jet nebulizer;
nebulization via membrane nebulizer;
nebulization via powder inhaler.

### Claim 11

A cutaneous bacteriophage material or composition, comprising
a) a sterile bacteriophage powder; or
b) a sterile bacteriophage sponge including a bacteriophage gel or a bacteriophage powder as wound dressing.

### Claim 12

A bacteriophage suture material or composition, comprising:
characterized in that
a) a monofilament surture material is circularly sprayed with a bacteriophage solution or with a bacteriophage gel or
b) a polyfilament suture material is wetted with a bacteriophage solution or with a bacteriophage gel, wherein the solution or gel is provided on the suture material and/or in the contact zones.

### Claim 13

A two-syringe bacteriophage material or compoisition, comprising:
a first syringe is prepared with a bacteriophage solution and a second syringe is prepared with a gel, the two syringes being connectable to each other, wherein mixing of the gel with the bacteriophage solution is possible and this mixture is then present in a syringe ready for application.

### Claim 14 (depends on 13)

The two-syringe bacteriophage means according to claim 13, whereindifferent gels and/or different bacteriophage solutions can be kept in stock for different combination among each other and accordingly mixed with each other to form a dedicated bacteriophage solution gel.

### Claim 15

A naso-pharyngeal and pulmonary bacteriophage material or composition, comprising:
a) a bacteriophage solution or a bacteriophage powder is nebulizable using at least one of the following devices, and the bacteriophage nebulization device is formed as:
a ventilator including a nebulization device or a pressurized gas-dosing aerosol chamber;
a pressurized gas metered dose aerosol applicator
a container inhalation arrangement including a nebulization chamber and a jet nebulizer or a membrane nebulizer;
an inhalation device including a pressurized gas metered-dose inhaler;
a powder inhaler.

### Claim 16

A bacteriophage sensitive testing application comprising bacteriophages, a bacterial nutrient solution, and a dye are arranged in a container, wherein the dye can interact with bacterial cell walls.